诺和诺德：启动买入评级，认为已触底 (NYSE:NVO)
· seekingalpha.com
诺和诺德的口服维格威 (Wegovy) 正在扩大肥胖治疗市场，而非仅仅是蚕食注射剂份额。阅读为何 NVO 股票值得买入。
Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU ...